RACAK
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π Esg
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
0
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Race Oncology Ltd - Option Expiring 16-May-2022 Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in RACAK
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in RACAK
N/A
RACAK investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in RACAK also invest in...
Want more shares? Try these...
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is focused on developing and commercializing radiopharmaceutical products and nuclear medicines for both therapeutic and diagnostic applications in precision oncology. The Companyβs subsidiary includes Radiopharm Theranostics (USA) Inc. The firm has a pipeline of four licensed platform technologies, Nano-monoclonal antibodies (mAbs), Pivalate, AVΞ²6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, RAD201, RAD202, RAD204, RAD205, RAD207, RAD301, RAD302, RAD401 and RAD402.
π Share price
$0.15 AUD
Race Oncology Ltd. is a precision oncology company, which engages in the discovery and development of the phase 2/3 cancer drug called Zantrene. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-07-13. Zantrene is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. The firm is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers. Zantrene (bisantrene dihydrochloride) is a small molecule anti-cancer drug which has clinical and preclinical efficacy as both a low dose, highly targeted precision oncology agent and a cardio-protective chemotherapeutic. The firm also has clinical data for the use of Zantrene as a chemotherapeutic agent with reduced cardiotoxicity in acute myeloid leukemia (AML), breast and ovarian cancers and is investigating its use in these areas.
π Share price